Anti-Obesity Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Anti-Obesity Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Anti-Obesity Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Anti-Obesity Therapeutics market. The report identifies the key trends shaping and driving the global Anti-Obesity Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anti-Obesity Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Anti-Obesity Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Anti-Obesity Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Anti-Obesity Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anti-Obesity Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Anti-Obesity Therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Anti-Obesity Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anti-Obesity Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Anti-Obesity Therapeutics market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ANTI-OBESITY THERAPEUTICS - INTRODUCTION

2.1 Overview
2.2 Epidemiology
2.3 Etiology
  2.3.1 Role of Energy Expenditure in the Development of Obesity
  2.3.2 Central Mechanism Regulate Energy Homeostasis
  2.3.3 Psychological Factors
  2.3.4 Endocrine Factors
  2.3.5 Genes and Environmental Factors
2.4 Symptoms
2.5 Diagnosis
2.6 Pathophysiology
  2.6.1 Role of Genetics in Obesity
2.7 Treatment
  2.7.1 Lifestyle Modification
  2.7.2 Dietary Interventions
  2.7.3 Behavioral Therapy
  2.7.4 Pharmacotherapy
  2.7.5 Surgical Interventions
2.8 GlobalData Pipeline Report Guidance

3 ANTI-OBESITY THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Anti-Obesity Therapeutics Market Size - Global (2005-2010)
3.2 Anti-Obesity Therapeutics Market Forecast - Global (2010-2018)
3.3 Anti-Obesity Therapeutics Market Size - The US (2005-2010)
3.4 Anti-Obesity Therapeutics Market Forecast - The US (2010-2018)
3.5 Anti-Obesity Therapeutics Market Size - France (2005-2010)
3.6 Anti-Obesity Therapeutics Market Forecast - France (2010-2018)
3.7 Anti-Obesity Therapeutics Market Size - Germany (2005-2010)
3.8 Anti-Obesity Therapeutics Market Forecast - Germany (2010-2018)
3.9 Anti-Obesity Therapeutics Market Size - Italy (2005-2010)
3.10 Anti-Obesity Therapeutics Market Forecast - Italy (2010-2018)
3.11 Anti-Obesity Therapeutics Market Size - Spain (2005-2010)
3.12 Anti-Obesity Therapeutics Market Forecast - Spain (2010-2018)
3.13 Anti-Obesity Therapeutics Market Size - The UK (2005-2010)
3.14 Anti-Obesity Therapeutics Market Forecast - The UK (2010-2018)
3.15 Anti-Obesity Therapeutics Market Size - Japan (2005-2010)
3.16 Anti-Obesity Therapeutics Market Forecast - Japan (2010-2018)
3.17 Drivers and Barriers for the Anti-Obesity Therapeutics Market
  3.17.1 Anti-Obesity Therapeutics Market Drivers
  3.17.2 Anti-Obesity Therapeutics Market Barriers
3.18 Opportunity and Unmet Need
3.19 Key Takeaway

4 ANTI-OBESITY THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Anti-Obesity Therapeutics
  4.3.1 Xenical (orlistat)
4.4 Key Takeaway

5 ANTI-OBESITY THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Anti-Obesity Therapeutics Market - Pipeline Assessment by Phase of Development
  5.3.1 Anti-Obesity Therapeutics - Filed and Phase III Pipeline
  5.3.2 Anti-Obesity Therapeutics - Phase II Pipeline
  5.3.3 Anti-Obesity Therapeutics - Phase I Pipeline
  5.3.4 Anti-Obesity Therapeutics - Preclinical Pipeline
  5.3.5 Anti-Obesity Therapeutics - Discovery Pipeline
5.4 Anti-Obesity Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Anti-Obesity Therapeutics Market - Most Promising Drugs Under Clinical Development
5.7 Most Promising Drug Profiles
  5.7.1 Contrave (bupropion SR/naltrexone)
  5.7.2 Cametor (cetilistat)
  5.7.3 Qnexa
  5.7.4 Lorqess (lorcaserin hydrochloride)
  5.7.5 Victoza (liraglutide)
5.8 Key Takeaway

6 ANTI-OBESITY THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials

7 ANTI-OBESITY THERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario

8 ANTI-OBESITY THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Arena Pharmaceuticals
  8.2.2 VIVUS, Inc
  8.2.3 Orexigen Therapeutics
  8.2.4 Norgine Limited
  8.2.5 Novo Nordisk
  8.2.6 Tabular Presentation Details of Other Companies in the Pipeline
  8.2.7 Key Takeaway

9 ANTI-OBESITY THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS, 2011

10 ANTI-OBESITY THERAPEUTICS - APPENDIX

10.1 Market Definitions
10.2 Acronyms
10.3 Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Obesity - Epidemiology
Table 2: Uncoupling Proteins in Humans
Table 3: Anti-Obesity Therapeutics - Classification of Underweight, Obese and Overweight
Table 4: Anti-Obesity Therapeutics Major Markets, Global, Revenue ($m), 2005-2010
Table 5: Anti-Obesity Therapeutics Major Markets, Global, Forecast ($m), 2010-2018
Table 6: Anti-Obesity Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 7: Anti-Obesity Therapeutics Market, The US, Forecast ($m), 2010-2018
Table 8: Anti-Obesity Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Anti-Obesity Therapeutics Market, France, Forecast ($m), 2010-2018
Table 10: Anti-Obesity Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Anti-Obesity Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 12: Anti-Obesity Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Anti-Obesity Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 14: Anti-Obesity Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Anti-Obesity Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 16: Anti-Obesity Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 17: Anti-Obesity Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 18: Anti-Obesity Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 19: Anti-Obesity Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 20: Anti-Obesity Therapeutics - Filed and Phase III Pipeline, 2011
Table 21: Anti-Obesity Therapeutics - Phase II Pipeline, 2011
Table 22: Anti-Obesity Therapeutics - Phase I Pipeline, 2011
Table 23: Anti-Obesity Therapeutics - Preclinical Pipeline, 2011
Table 24: Anti-Obesity Therapeutics - Discovery Pipeline, 2011
Table 25: Anti-Obesity Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 26: Anti-Obesity Therapeutics, Major Markets - Clinical Trials by Country, 2011
Table 27: Anti-Obesity Therapeutics, Major Markets - Clinical Trials by Phase, 2011
Table 28: Anti-Obesity Therapeutics, Major Markets - Clinical Trials by Development Status, 2011
Table 29: Anti-Obesity Therapeutics, Major Markets - Overall Sponsors, 2011
Table 30: Anti-Obesity Therapeutics, Major Markets - Prominent Sponsors, 2011
Table 31: Anti-Obesity Therapeutics, Major Markets - Companies Participating in Clinical Trials, 2011
Table 32: Arena Pharmaceuticals Pipeline Products, 2011
Table 33: VIVUS, Inc Pipeline Products, 2011
Table 34: Orexigen Therapeutics, Pipeline Products, 2011
Table 35: Norgine Limited, Pipeline Products, 2011
Table 36: Novo Nordisk Pipeline Products, 2011
Table 37: Description of Other Companies in the Pipeline, 2011
Table 38: Anti-Obesity Therapeutics, Global, Deals, 2011

LIST OF FIGURES

Figure 1: Representation of Peptides Secreted by Gut and Adipose Controls Energy Balance
Figure 2: Treatment and Management of Obesity
Figure 3: Anti-Obesity Therapeutics Major Market, Global, Revenue ($m), 2005-2010
Figure 4: Anti-Obesity Therapeutics Major Market, Global, Forecast ($m), 2010-2018
Figure 5: Anti-Obesity Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 6: Anti-Obesity Therapeutics Market, The US, Forecast ($m), 2010-2018
Figure 7: Anti-Obesity Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 8: Anti-Obesity Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 9: Anti-Obesity Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 10: Anti-Obesity Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 11: Anti-Obesity Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 12: Anti-Obesity Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 13: Anti-Obesity Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 14: Anti-Obesity Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 15: Anti-Obesity Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 16: Anti-Obesity Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 17: Anti-Obesity Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 18: Anti-Obesity Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 19: Opportunity and Unmet Need in the Anti-Obesity Therapeutics Market, 2011
Figure 20: Anti-Obesity Therapeutics - Strategic Competitor Assessment, 2011
Figure 21: Anti-Obesity Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 22: Anti-Obesity Therapeutics - Pipeline by Phase of Development, 2011
Figure 23: Anti-Obesity Therapeutics - Technology Trends Analytics Framework, 2011
Figure 24: Anti-Obesity Therapeutics - Technology Trends Analytics Framework Description, 2011
Figure 25: Anti-Obeisty Therapeutics, Major Markets - Clinical Trials by Country, 2011
Figure 26: Anti-Obesity Therapeutics, Major Markets - Clinical Trials by Phase, 2011
Figure 27: Anti-Obesity Therapeutics, Major Markets - Clinical Trials by Development Status, 2011
Figure 28: Anti-Obesity Therapeutics, Major markets - Overall Sponsors, 2011
Figure 29: Anti-Obesity Therapeutics, Major markets - Prominent Sponsors, 2011
Figure 30: Anti-Obesity Therapeutics, Major markets - Clinical Trials of Top Ten Companies by Phase, 2011
Figure 31: Anti-Obesity Therapeutics Market, Drivers and Barriers 2011
Figure 32: Implications for Future Market Competition in the Anti-Obesity Therapeutics Market, 2011
Figure 33: Anti-Obesity Therapeutics Market - Pipeline by Company, 2011
Figure 34: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Arena Pharmaceuticals
VIVUS, Inc
Orexigen Therapeutics
Norgine Limited
Novo Nordisk Skip to top